HRP960503B1 - (-) cis-6(s)-phenyl-5(r)/4-(2-pyrrolidin-1-ylethoxy)-5,6,7,8-tetrahydronaphthalen-2-ol d-tartarate - Google Patents

(-) cis-6(s)-phenyl-5(r)/4-(2-pyrrolidin-1-ylethoxy)-5,6,7,8-tetrahydronaphthalen-2-ol d-tartarate

Info

Publication number
HRP960503B1
HRP960503B1 HR960503A HRP960503A HRP960503B1 HR P960503 B1 HRP960503 B1 HR P960503B1 HR 960503 A HR960503 A HR 960503A HR P960503 A HRP960503 A HR P960503A HR P960503 B1 HRP960503 B1 HR P960503B1
Authority
HR
Croatia
Prior art keywords
ylethoxy
tetrahydronaphthalen
tartarate
pyrrolidin
cis
Prior art date
Application number
HR960503A
Other languages
English (en)
Inventor
Charles K Chiu
Morgan Meltz
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP960503A2 publication Critical patent/HRP960503A2/hr
Publication of HRP960503B1 publication Critical patent/HRP960503B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HR960503A 1995-11-02 1996-10-29 (-) cis-6(s)-phenyl-5(r)/4-(2-pyrrolidin-1-ylethoxy)-5,6,7,8-tetrahydronaphthalen-2-ol d-tartarate HRP960503B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US612595P 1995-11-02 1995-11-02

Publications (2)

Publication Number Publication Date
HRP960503A2 HRP960503A2 (en) 1998-04-30
HRP960503B1 true HRP960503B1 (en) 2001-12-31

Family

ID=21719433

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960503A HRP960503B1 (en) 1995-11-02 1996-10-29 (-) cis-6(s)-phenyl-5(r)/4-(2-pyrrolidin-1-ylethoxy)-5,6,7,8-tetrahydronaphthalen-2-ol d-tartarate

Country Status (43)

Country Link
US (1) US5948809A (ja)
EP (1) EP0876359B1 (ja)
JP (1) JP3088020B2 (ja)
KR (1) KR19990067280A (ja)
CN (1) CN1067065C (ja)
AP (1) AP713A (ja)
AR (1) AR004078A1 (ja)
AT (1) ATE248827T1 (ja)
AU (1) AU708841B2 (ja)
BG (1) BG63943B1 (ja)
BR (1) BR9611436A (ja)
CA (1) CA2236673C (ja)
CO (1) CO4770967A1 (ja)
CZ (1) CZ287341B6 (ja)
DE (1) DE69629837T2 (ja)
DK (1) DK0876359T3 (ja)
DZ (1) DZ2114A1 (ja)
EG (1) EG21095A (ja)
ES (1) ES2203713T3 (ja)
GT (1) GT199600085A (ja)
HR (1) HRP960503B1 (ja)
HU (1) HU227521B1 (ja)
IL (1) IL124027A (ja)
IS (1) IS1855B (ja)
MA (1) MA23998A1 (ja)
NO (1) NO310358B1 (ja)
NZ (1) NZ318498A (ja)
OA (1) OA11009A (ja)
PE (1) PE17698A1 (ja)
PL (1) PL188633B1 (ja)
PT (1) PT876359E (ja)
RO (1) RO119829B1 (ja)
RU (1) RU2162465C2 (ja)
SI (1) SI0876359T1 (ja)
SK (1) SK282172B6 (ja)
TN (1) TNSN96134A1 (ja)
TR (1) TR199800783T2 (ja)
TW (2) TW581766B (ja)
UA (1) UA51676C2 (ja)
UY (1) UY24362A1 (ja)
WO (1) WO1997016434A1 (ja)
YU (1) YU49123B (ja)
ZA (1) ZA969212B (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) * 1997-02-14 1997-04-02 Smith & Nephew Compositions
ATE265853T1 (de) * 1998-06-16 2004-05-15 Pfizer Prod Inc Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2
AR018869A1 (es) * 1998-06-16 2001-12-12 Pfizer Prod Inc Composicion farmaceutica, su uso para la preparacion de medicamentos y estuche que la contiene
JP2002518328A (ja) * 1998-06-16 2002-06-25 ファイザー・プロダクツ・インク 筋骨格虚弱の治療用の（選択的）エストロゲン受容体モジュレーター（ｓｅｒｍ）および成長ホルモン分泌促進薬（ｇｈｓ）の治療的組合せ
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271696A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
DK1268453T3 (da) * 2000-04-07 2006-10-23 Pfizer Prod Inc Östrogen agonist/antagonist metabolitter
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
ES2274854T3 (es) 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
CZ20032959A3 (cs) 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
WO2003011282A1 (en) * 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
RU2317104C2 (ru) * 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
KR100636953B1 (ko) * 2002-03-28 2006-10-19 화이자 프로덕츠 인코포레이티드 정제된 라소폭시펜 및 재결정화에 의한 라세미라소폭시펜의 정제 방법
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
MXPA06015170A (es) * 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.
US20070249623A1 (en) * 2004-06-30 2007-10-25 Eli Lilly And Company Patent Division 1-(Indole-6-Carbonyl-D-Phenylglycinyl)-4-(1-Methylpiperidin-4-Yl)Piperazine D-Tartrate
WO2006136944A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride
CZ2007373A3 (cs) * 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US8937188B2 (en) 2009-04-29 2015-01-20 Glenmark Generics Ltd. Process for the preparation of lasofoxifene tartrate
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) * 2013-02-05 2015-11-11 南京华威医药科技开发有限公司 酒石酸拉索昔芬中间体的制备方法
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234090A (en) * 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
HUP9900087A2 (hu) 1999-05-28
AU6998496A (en) 1997-05-22
IS1855B (is) 2003-02-21
CZ132098A3 (cs) 1999-03-17
UY24362A1 (es) 1997-04-24
TNSN96134A1 (fr) 1998-12-31
EP0876359A1 (en) 1998-11-11
YU57896A (sh) 1998-12-23
CA2236673C (en) 2002-03-19
AU708841B2 (en) 1999-08-12
HRP960503A2 (en) 1998-04-30
CN1067065C (zh) 2001-06-13
EP0876359B1 (en) 2003-09-03
NO310358B1 (no) 2001-06-25
DE69629837D1 (de) 2003-10-09
AP9600880A0 (en) 1997-01-31
YU49123B (sh) 2004-03-12
CO4770967A1 (es) 1999-04-30
TR199800783T2 (xx) 1998-08-21
MA23998A1 (fr) 1997-07-01
JPH11502866A (ja) 1999-03-09
UA51676C2 (uk) 2002-12-16
MX9803544A (es) 1998-09-30
KR19990067280A (ko) 1999-08-16
EG21095A (en) 2000-10-31
NO981962D0 (no) 1998-04-30
BR9611436A (pt) 1999-03-23
SK54298A3 (en) 1999-07-12
CN1201458A (zh) 1998-12-09
RU2162465C2 (ru) 2001-01-27
DK0876359T3 (da) 2003-11-24
BG102474A (en) 1999-06-30
ATE248827T1 (de) 2003-09-15
SI0876359T1 (en) 2003-12-31
NZ318498A (en) 1999-06-29
DZ2114A1 (fr) 2002-07-22
PL326498A1 (en) 1998-09-28
CZ287341B6 (en) 2000-10-11
HUP9900087A3 (en) 1999-11-29
TW581766B (en) 2004-04-01
US5948809A (en) 1999-09-07
NO981962L (no) 1998-04-30
TW518327B (en) 2003-01-21
SK282172B6 (sk) 2001-11-06
IL124027A (en) 2001-10-31
ZA969212B (en) 1998-05-04
AR004078A1 (es) 1998-09-30
BG63943B1 (bg) 2003-07-31
WO1997016434A1 (en) 1997-05-09
CA2236673A1 (en) 1997-05-09
ES2203713T3 (es) 2004-04-16
RO119829B1 (ro) 2005-04-29
OA11009A (en) 2003-03-03
AP713A (en) 1998-12-28
PT876359E (pt) 2003-12-31
PL188633B1 (pl) 2005-03-31
JP3088020B2 (ja) 2000-09-18
GT199600085A (es) 1998-04-04
PE17698A1 (es) 1998-04-18
DE69629837T2 (de) 2004-05-06
HU227521B1 (en) 2011-07-28
IS4718A (is) 1998-04-16

Similar Documents

Publication Publication Date Title
HRP960503B1 (en) (-) cis-6(s)-phenyl-5(r)/4-(2-pyrrolidin-1-ylethoxy)-5,6,7,8-tetrahydronaphthalen-2-ol d-tartarate
AU7039994A (en) Exercise machine
AU1587795A (en) Improved hemming machine
AU2990895A (en) Sewing machine
ZA958161B (en) Process for preparing 1,3-alkanediols and 3-hydroxyaldehydes
ZA958160B (en) Process for preparing 1,3-alkanediols and 3-hydroxyaldehydes
GB9413980D0 (en) Novel agrochemical formulation
AU5777390A (en) Press machine
AU696614B2 (en) Gas-heated apparatus
AU5828990A (en) Beeper amplifier
AU3744495A (en) Process for preparing 1,3-alkanediols and 3-hydroxyldehydes
AU1754095A (en) Calender
AU2160695A (en) Sewing template
AU618696B1 (en) Embossing apparatus
AU4715196A (en) Desaminononapeptides, process for preparing the same and their use for preparing elcatonin
AU7215991A (en) Cloth-inspection machine
GB9308720D0 (en) Audiometric measurements
AU7814891A (en) Block press
AU639353B2 (en) Quaternary-quaternary diamine
AU686987B3 (en) Sewing template
AU8979691A (en) Sandbagging machine
GB9309033D0 (en) Adjustable bearing and machine slide
AUPM569094A0 (en) Exercise machine
AU2533695A (en) Presser apparatus
AUPM716294A0 (en) Adjustable template

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20111011

Year of fee payment: 16

PBON Lapse due to non-payment of renewal fee

Effective date: 20121030